
Liminal BioSciences Net Income | LMNL
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Liminal BioSciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 622 K | 12.2 M | -119 M | -207 M | -238 M | -120 M | -101 M | -51 M | 5.94 M | -16.5 M | 230 K | -2.55 M |
Annual performance
Select metrics to display
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.2 M | -238 M | -69.6 M |
Quarterly Net Income Liminal BioSciences
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.14 M | 622 K | - | -6.22 M | - | 12.2 M | - | -32.1 M | - | -119 M | - | -27.8 M | - | -207 M | - | -134 M | - | -238 M | - | - | - | -120 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.2 M | -238 M | -80 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
-28.9 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-106 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-28.5 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-132 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-34.4 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-215 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-130 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-207 M | $ 3.62 | 4.18 % | $ 561 M | ||
|
Acasti Pharma
ACST
|
-7.79 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
321 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-405 K | - | -4.36 % | $ 27 M | ||
|
Idera Pharmaceuticals
IDRA
|
-23.4 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-173 M | - | - | $ 69.7 B | ||
|
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-10.3 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-54.6 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
5 M | - | 368.57 % | $ 41.9 M | ||
|
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
158 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
3.01 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-223 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-11.3 M | - | -8.77 % | $ 12.4 M | ||
|
Bristol-Myers Squibb Company
BMY
|
7.05 B | $ 59.5 | -3.02 % | $ 121 B | ||
|
Cidara Therapeutics
CDTX
|
-170 M | - | - | $ 1.41 B | ||
|
BioLineRx Ltd.
BLRX
|
-2.03 M | $ 1.1 | -1.79 % | $ 2.71 B | ||
|
Iterum Therapeutics
ITRM
|
-24.8 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-12.1 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-15.2 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-52.5 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-34.2 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-241 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-21.9 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-41 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-65.2 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-43.6 M | - | - | $ 728 M | ||
|
NGM Biopharmaceuticals
NGM
|
-142 M | - | - | $ 127 M | ||
|
Regulus Therapeutics
RGLS
|
-46.4 M | - | - | $ 155 M | ||
|
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | ||
|
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M |